Europe Contract Development and Manufacturing Organization (CDMO) Market - Size, Share Outlook, Growth Analysis Report and Forecast Trends (2026-2035)

The Europe contract development and manufacturing organization (CDMO) market was valued at USD 70.86 Billion in 2025. It is poised to grow at a CAGR of 9.80% during the forecast period of 2026-2035, and reach USD 180.48 Billion by 2035. The market is driven by the increasing pharmaceutical outsourcing due to cost efficiency, specialized expertise, and complex drug development requirements. The adoption of advanced biologics, cell and gene therapies, and precision medicines is expected to accelerate demand for CDMO services during the forecast period. The expansion of integrated development-to-manufacturing capabilities and technological advancements in automation and flexible production will further support long-term growth.

Key Market Trends and Insights

• By service type, the contract manufacturing organization segment held approximately 65% of the share in the historical period.
• Based on the therapeutic area, the oncological diseases segment accounted for the major share in the historical period.
• By end user, the pharmaceutical and biopharmaceutical companies segment led the market in the historical period.

Market Size and Forecast

• Market Size (2025): USD 70.86 Billion
• Projected Market Size (2035): USD 180.48 Billion
• CAGR (2026-2035): 9.80%

Europe Contract Development and Manufacturing Organization (CDMO) Market Overview

Contract development and manufacturing organizations play a pivotal role in the pharmaceutical and biotechnology ecosystem by supporting companies at all stages of drug discovery, development, and manufacturing. The market is expanding steadily due to increasing outsourcing trends, complex biologics pipelines, and demand for flexible manufacturing solutions. The market was valued at USD 70.86 Billion in 2025. The growth is further supported by rising Manufacturing investments, strategic partnerships, and technological advancements, improving scalability, compliance, and production efficiency.

Europe Contract Development and Manufacturing Organization (CDMO) Market Growth Drivers

Cost-Efficient Biologics Capacity Expansion to Accelerate the Market Landscape

The expansion of cost-efficient biologics manufacturing capacity across Europe is a key driver supporting the contract development and manufacturing organization (CDMO) market. In August 2025, Rezon Bio announced its launch as a European biologics CDMO with mirrored, regulator-audited facilities in Poland, offering end-to-end services from cell line development to GMP manufacturing and commercialization. The company integrates single-use technologies and AI -enabled process optimization to shorten development timelines and reduce costs for clients. Such investments strengthen regional outsourcing capabilities, enhance competitiveness, and support the sustained expansion of the market.

Europe Contract Development and Manufacturing Organization (CDMO) Market Trends

Some of the notable trends in the market include strategic facility acquisitions, capacity expansion, and the increasing expansion of integrated CDMO service models.

Strategic Facility Acquisitions and Capacity Expansion to Boost the Market Value

The strategic acquisitions of advanced manufacturing facilities are emerging as a key trend, strengthening service capabilities and geographic reach in the market. Companies are increasingly investing in integrated drug product and device assembly solutions to meet growing demand for biologics and injectable therapies. For instance, in October 2025, Terumo Corporation enhanced its European footprint by acquiring a pharmaceutical production facility from WuXi Biologics in Leverkusen, strengthening fill-finish and device assembly capabilities. Such strategic expansions are expected to accelerate innovation and drive sustained market growth across Europe.

Growing Expansion of Integrated Service Models is Likely to Enhance the Contract Development and Manufacturing Organization (CDMO) Market Demand

The market is witnessing a growing trend toward the formalization of integrated CMO/CDMO service models, enabling pharmaceutical companies to optimize existing infrastructure and diversify revenue streams through outsourcing partnerships. For instance, in June 2024, Towa International announced the launch of an official CMO/CDMO business line at its Barcelona facility to support external drug development and manufacturing needs. Such strategic initiatives reflect increasing collaboration across the pharmaceutical value chain, strengthening service capacity and innovation capabilities, and are expected to drive sustained market growth across the region.

Europe Contract Development and Manufacturing Organization (CDMO) Market Segmentation

Market Breakup by Service Type

• Contract Manufacturing Organization
• Active Pharmaceutical Ingredient (API) Manufacturing Small Molecule Large Molecule High Potency (HPAPI)
• Finished Formulation (FDF) Development and Manufacturing Solid Dose Formulation Liquid Dose Formulation Injectable Dose Formulation Secondary Packaging Services Others
• Contract Research Organization
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Market Breakup by Therapeutic Area

• Oncological Diseases
• Metabolic Disorders
• Neurological Disorders
• Respiratory Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Others

Market Breakup by End User

• Pharmaceutical and Biopharmaceutical Companies
• Medical Devices Companies
• Others

Market Breakup by Region

• Germany
• United Kingdom
• France
• Italy
• Others

Europe Contract Development and Manufacturing Organization (CDMO) Market Share

Oncological Diseases Segment is Poised to Dominate the Market Segmentation by Therapeutic Area

The market is segmented by therapeutic area into oncology, cardiovascular, infectious, and other therapeutic areas. Among these, oncological diseases are expected to lead, driven by increasing cancer prevalence and the growing need for specialized biologics development and manufacturing capabilities. According to the Organisation for Economic Co-operation and Development (OECD), cancer remains a major public health challenge in the United Kingdom, with 1 in 4 premature deaths projected to be cancer-related between 2023 and 2050. This escalating disease burden is reinforcing demand for advanced outsourcing services, supporting sustained segment expansion.

Europe Contract Development and Manufacturing Organization (CDMO) Market Analysis by Region

The regions included in the report are Germany, the United Kingdom, France, Italy, and others. Among these, Germany leads the market, supported by its robust pharmaceutical manufacturing ecosystem, skilled workforce, and strong investment pipeline. In May 2025, Famar, backed by MidEuropa, announced the acquisition of a sterile manufacturing facility in Homburg from MiP Pharma to expand aseptic and lyophilized fill-finish capabilities. This transaction strengthens Germany’s position by addressing capacity gaps in high-quality sterile infrastructure and enhancing regional CDMO competitiveness.

Leading Players in the Europe Contract Development and Manufacturing Organization (CDMO) Market

The key features of the market report comprise funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Vetter Pharma-Fertigung GmbH & Co. KG

Vetter Pharma-Fertigung GmbH & Co. KG is a pharmaceutical service provider specializing in aseptic manufacturing and comprehensive fill-and-finish solutions from clinical development through commercial production. The company offers drug product development, aseptic filling with visual inspection, device assembly and packaging, analytical testing, regulatory support, and logistics services. With more than 7,300 employees and over one billion euros in annual sales from specialized filling services, Vetter actively supports biopharmaceutical partners in advancing complex injectable therapies. Its continued operational growth and infrastructure investments reinforce its position as a reliable partner in the contract development and manufacturing organization (CDMO) market.

Recipharm AB

Recipharm AB is a contract development and manufacturing organization offering end-to-end solutions across pharmaceutical development and production. The company provides development and manufacturing for solid, semi-solid, and liquid dosage forms, alongside sterile fill-and-finish services for biologics and small molecules. Its Advanced Bio capabilities include good manufacturing practice production of advanced therapy medicinal products such as plasmids, xRNA, and viral vectors. With 16 facilities across eight countries and services supporting more than 100 markets, the company plays a significant role in enabling efficient drug development, scale-up, and commercialization for pharmaceutical partners.

Boehringer Ingelheim

Boehringer Ingelheim is a pharmaceutical company with a strong presence in contract development and manufacturing through its BioXcellence™ division. The company provides end-to-end services for biopharmaceutical production, including mammalian and microbial manufacturing and aseptic filling for late-stage biologics. With more than four decades of biotechnology expertise and a global manufacturing network, it has supported the commercialization of over 45 therapies. Its planned participation at DCAT Week 2026 highlights ongoing engagement with industry partners, reinforcing its role as a trusted collaborator in advancing complex biologic therapies.

Pfizer Inc.

Pfizer Inc. plays a significant role in the contract development and manufacturing space through its Pfizer CentreOne division, offering end-to-end services for pharmaceutical partners. The company specializes in commercial manufacturing of sterile injectables, oral solid dose products, and biologic drug products, including antibody-drug conjugates supported by decades of technical expertise. Its capabilities also extend to regulatory support, intellectual property protection, and technology transfer solutions across more than 150 countries. By leveraging advanced infrastructure and global networks, Pfizer helps accelerate therapy development timelines and improve patient access to high-quality medicines.

Other key players in the market are Patheon Pharma Services (Thermo Fisher Scientific Inc.), Famar SA, Lonza Group, LTS Lohmann Therapie-Systeme AG, Aenova Holding GmBH, Fareva SA, FUJIFILM Diosynth Biotechnologies, eXmoor Pharma, B. Braun SE, and Sanofi.

Key Questions Answered in the Europe Contract Development and Manufacturing Organization (CDMO) Market

• What was the Europe contract development and manufacturing organization (CDMO) market value in 2025?
• What is the Europe contract development and manufacturing organization (CDMO) market forecast outlook for 2026-2035?
• What major factors aid the demand for the Europe contract development and manufacturing organization (CDMO) market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major Europe contract development and manufacturing organization (CDMO) market trends?
• Which service type is expected to dominate the market segment?
• Which therapeutic area is projected to lead the market segment?
• Which end user is anticipated to drive the market segment?
• Who are the key players in the Europe contract development and manufacturing organization (CDMO) market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?